Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors for manipulability and tolerance of transgenes. Poor tumour-selectivity, off-target sequestration and immune inactivation hamper clinical efficacy. We sought to completely redesign Ad5 into a refined, tumour selective virotherapy targeted to αvβ6 integrin, which is expressed in a range of aggressively transformed epithelial cancers but non-detectable in healthy tissues. Experimental Design: Ad5NULL-A20 harbours mutations in each major capsid protein to preclude uptake via all native pathways. Tumour-tropism via αvβ6-targeting was achieved by genetic insertion of A20 peptide (NAVPNLRGDLQVLAQKVART) within the fiber knob protein. The vector's s...
Ovarian cancer is the deadliest gynaecological cancer, with less than half of patients surviving fiv...
More people are surviving longer with cancer. Whilst this can be partially attributed to advances in...
The use of intraperitoneal (i.p.) adenovirus virotherapy of ovarian cancer is currently limited by i...
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors...
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors...
We previously developed a refined, tumor-selective adenovirus, Ad5NULL-A20, harboring tropism ablati...
Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapie...
Metastatic pancreatic ductal adenocarcinomas (PDAC) are incurable due to the rapid development of re...
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic viroth...
Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) ...
AbstractVirotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and...
Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) ...
Adenoviruses (Ad) are commonly used both experimentally and clinically, including oncolytic virother...
A key impediment to successful cancer therapy with adenoviral vectors is the inefficient transductio...
Virotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and clinica...
Ovarian cancer is the deadliest gynaecological cancer, with less than half of patients surviving fiv...
More people are surviving longer with cancer. Whilst this can be partially attributed to advances in...
The use of intraperitoneal (i.p.) adenovirus virotherapy of ovarian cancer is currently limited by i...
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors...
Purpose: Virotherapies are maturing in the clinical setting. Adenoviruses (Ad) are excellent vectors...
We previously developed a refined, tumor-selective adenovirus, Ad5NULL-A20, harboring tropism ablati...
Encouraging results from recent clinical trials are revitalizing the field of oncolytic virotherapie...
Metastatic pancreatic ductal adenocarcinomas (PDAC) are incurable due to the rapid development of re...
The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic viroth...
Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) ...
AbstractVirotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and...
Oncolytic virotherapies (OV) hold immense clinical potential. OV based on human adenoviruses (HAdV) ...
Adenoviruses (Ad) are commonly used both experimentally and clinically, including oncolytic virother...
A key impediment to successful cancer therapy with adenoviral vectors is the inefficient transductio...
Virotherapy of cancer using oncolytic adenoviruses has shown promise in both preclinical and clinica...
Ovarian cancer is the deadliest gynaecological cancer, with less than half of patients surviving fiv...
More people are surviving longer with cancer. Whilst this can be partially attributed to advances in...
The use of intraperitoneal (i.p.) adenovirus virotherapy of ovarian cancer is currently limited by i...